Concurrent dendritic cell vaccine and strontium-89 radiation therapy in the management of multiple bone metastases

Abstract

The study has important implications for that combined 89Sr radiation, and DC vaccine therapy can benefit cancer patients with bone metastasis.

Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline

“…[17][18][19][20][21][22][23][24][25][26][27][28] Most intriguing is the growing evidence that, in patients with bone-only or bone-dominant disease, these agents may provide benefits beyond pain relief, including prevention of skeletal-related events and improved survival, although appropriate use of radiopharmaceuticals with the intention of improving survival is not addressed in this guideline. 18,29,30 Regarding the benefit of EBRT, a phase 3 RCT of samarium-153 with or without EBRT (8 Gy × 1 in 90% receiving EBRT) in metastatic prostate cancer with painful bony metastases demonstrated a significant improvement in pain relief with addition of EBRT and no extra toxicity. 17…”

Osteoimmuno-Oncology: Therapeutic Opportunities for Targeting Immune Cells in Bone Metastasis

“…The prevention of metastases is seen with mature DCs and 5-FU treatment [ 78 ]. Combination of stontium-89 and DC vaccination therapy provides a good response in patients with bone metastases [ 111 ]. Activation of DC with tumor-lysates and combination with anti-CTLA-4 treatment increases the number of CD8+ T cells, decreases the number of Tregs, and inhibits metastatic growth [ 112 ].…”

Trial watch: Dendritic cell-based anticancer therapy

“…233,238,256,262,263 As for the main oncological indications investigating in this context, 7 trials enrolled melanoma patients, 226,230,236,238,250,251 4 subjects with pancreatic carcinoma, 220,227,228,248 4 women with breast carcinoma, 222,255,258,260 4 patients with various brain tumors, including glioblastoma; 234,242,249,252 3 ovarian carcinoma patients, 229,235 and the others a broad panel of hematological and solid neoplasms. 221,224,225,[231][232][233]237,[239][240][241]243,244,246,247,253,254,256,257,259,261 Taken together, the results of these studies (the majority of which was Phase I or II trials) indicate that DC-based anticancer interventions are generally well tolerated and elicit anticancer immune responses that, at least in a fraction of patients, underpin objective c...…”

“…259 Finally, the DC-based immunotherapeutic regimens employed in 2 of these studies could not be determined, owing to the lack of access to the corresponding reports. 260,261 In many instances, DCs were employed as standalone therapeutic agents, i.e., administered in the presence of standard adjuvants only. [221][222][223][224][225]229,232,234,240,243,245,246,[249][250][251] Alternatively, DC-based interventions were administered together with cytokine-induced killer (CIK) cells, 220,233,247,[252][253][254][255] adoptively transferred T lymphocytes, 226,236,239,248,256,259 chemotherapy, 227,228,237 immunostimulatory cytokines, 230,235,242 TLR agonists, 257 or radiation therapy.…”